Maraviroc, a clinically approved CCR5 antagonist, selectively blocked antigen-bearing monocytes from reaching the lymph node without affecting DC migration, and in prophylactic settings, markedly improved anti-tumor responses. Here, CCR5 is linked to neoplasm.